BACKGROUND: We report results of a phase I trial designed to estimate the maximum tolerated dose (MTD), describe dose-limiting toxicities (DLT), and characterize the pharmacokinetic profile of MK-2206, an AKT inhibitor, in children with refractory or recurrent malignancies. PROCEDURE: MK-2206 was administered either every other day (Schedule 1), or once a week (Schedule 2) in a 28-day cycle. Dose escalations in increments of ∼30% were independently made in each part using the rolling-six design. Serial pharmacokinetic (PK) studies were obtained. Biological studies include analysis of PI3K/PTEN/AKT-cell signaling pathway in pre and post-therapy in PBMC and in tumors at diagnosis or recurrence. RESULTS: Fifty patients (26 males, median age 12.6 years [range, 3.1-21.9]) with malignant glioma (16), ependymoma (4), hepatocellular carcinoma (3), gliomatosis cereberi (2), or other tumors (22) were enrolled; 40 were fully evaluable for toxicity (Schedule 1, n = 23; Schedule 2, n = 17). Schedule 1 DLTs included: grade 3 dehydration in 1/6 patients at 28 mg/m(2) ; grade 4 hyperglycemia and neutropenia in 1/6 patients at 45 mg/m(2) ; and grade 3 rash in 3/6 patients at dose level 4 (58 mg/m(2) ). Schedule 2 DLTs included: grade 3 alkaline phosphatase in 1/6 patients at 90 mg/m(2) ; grade 3 rash in 1/6 patients at 120 mg/m(2) ; and grade 3 rash in 2/6 patients at 155 mg/m(2) . CONCLUSIONS: The recommended pediatric phase 2 dose of MK-2206 is 45 mg/m(2) /dose every other day or 120 mg/m(2) /dose weekly. PK appeared linear over the dose range studied.
BACKGROUND: We report results of a phase I trial designed to estimate the maximum tolerated dose (MTD), describe dose-limiting toxicities (DLT), and characterize the pharmacokinetic profile of MK-2206, an AKT inhibitor, in children with refractory or recurrent malignancies. PROCEDURE: MK-2206 was administered either every other day (Schedule 1), or once a week (Schedule 2) in a 28-day cycle. Dose escalations in increments of ∼30% were independently made in each part using the rolling-six design. Serial pharmacokinetic (PK) studies were obtained. Biological studies include analysis of PI3K/PTEN/AKT-cell signaling pathway in pre and post-therapy in PBMC and in tumors at diagnosis or recurrence. RESULTS: Fifty patients (26 males, median age 12.6 years [range, 3.1-21.9]) with malignant glioma (16), ependymoma (4), hepatocellular carcinoma (3), gliomatosis cereberi (2), or other tumors (22) were enrolled; 40 were fully evaluable for toxicity (Schedule 1, n = 23; Schedule 2, n = 17). Schedule 1 DLTs included: grade 3 dehydration in 1/6 patients at 28 mg/m(2) ; grade 4 hyperglycemia and neutropenia in 1/6 patients at 45 mg/m(2) ; and grade 3 rash in 3/6 patients at dose level 4 (58 mg/m(2) ). Schedule 2 DLTs included: grade 3 alkaline phosphatase in 1/6 patients at 90 mg/m(2) ; grade 3 rash in 1/6 patients at 120 mg/m(2) ; and grade 3 rash in 2/6 patients at 155 mg/m(2) . CONCLUSIONS: The recommended pediatric phase 2 dose of MK-2206 is 45 mg/m(2) /dose every other day or 120 mg/m(2) /dose weekly. PK appeared linear over the dose range studied.
Authors: P Therasse; S G Arbuck; E A Eisenhauer; J Wanders; R S Kaplan; L Rubinstein; J Verweij; M Van Glabbeke; A T van Oosterom; M C Christian; S G Gwyther Journal: J Natl Cancer Inst Date: 2000-02-02 Impact factor: 13.506
Authors: T Camerini; L Mariani; G De Palo; E Marubini; M G Di Mauro; A Decensi; A Costa; U Veronesi Journal: J Clin Oncol Date: 2001-03-15 Impact factor: 44.544
Authors: Wolfgang Hartmann; Boris Digon-Söntgerath; Arend Koch; Anke Waha; Elmar Endl; Indra Dani; Dorota Denkhaus; Cynthia G Goodyer; Niels Sörensen; Otmar D Wiestler; Torsten Pietsch Journal: Clin Cancer Res Date: 2006-05-15 Impact factor: 12.531
Authors: Katherine Stemke-Hale; Ana Maria Gonzalez-Angulo; Ana Lluch; Richard M Neve; Wen-Lin Kuo; Michael Davies; Mark Carey; Zhi Hu; Yinghui Guan; Aysegul Sahin; W Fraser Symmans; Lajos Pusztai; Laura K Nolden; Hugo Horlings; Katrien Berns; Mien-Chie Hung; Marc J van de Vijver; Vicente Valero; Joe W Gray; René Bernards; Gordon B Mills; Bryan T Hennessy Journal: Cancer Res Date: 2008-08-01 Impact factor: 12.701
Authors: A Bellacosa; D de Feo; A K Godwin; D W Bell; J Q Cheng; D A Altomare; M Wan; L Dubeau; G Scambia; V Masciullo; G Ferrandina; P Benedetti Panici; S Mancuso; G Neri; J R Testa Journal: Int J Cancer Date: 1995-08-22 Impact factor: 7.396
Authors: Lindsey M Hoffman; Maryam Fouladi; James Olson; Vinay M Daryani; Clinton F Stewart; Cynthia Wetmore; Mehmet Kocak; Arzu Onar-Thomas; Lars Wagner; Sridharan Gururangan; Roger J Packer; Susan M Blaney; Amar Gajjar; Larry E Kun; James M Boyett; Richard J Gilbertson Journal: Childs Nerv Syst Date: 2015-05-01 Impact factor: 1.475
Authors: Lucas Moreno; Andrew D J Pearson; Xavier Paoletti; Irene Jimenez; Birgit Geoerger; Pamela R Kearns; C Michel Zwaan; Francois Doz; Andre Baruchel; Josef Vormoor; Michela Casanova; Stefan M Pfister; Bruce Morland; Gilles Vassal Journal: Nat Rev Clin Oncol Date: 2017-05-16 Impact factor: 66.675
Authors: Daniel N Cagney; Joohee Sul; Raymond Y Huang; Keith L Ligon; Patrick Y Wen; Brian M Alexander Journal: Neuro Oncol Date: 2018-08-02 Impact factor: 12.300
Authors: Jennifer R Smith; Lucas Moreno; Simon P Heaton; Louis Chesler; Andrew D J Pearson; Michelle D Garrett Journal: Mol Oncol Date: 2015-11-19 Impact factor: 6.603
Authors: Valerie A Granados; Usha Avirneni-Vadlamudi; Pooja Dalal; Samuel R Scarborough; Kathleen A Galindo; Priya Mahajan; Rene L Galindo Journal: Cancer Res Date: 2019-07-22 Impact factor: 12.701